Epilepsy Surgery Articles & Analysis
5 news found
The letter recaps the key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond directed at developing the Evo® platform thin film electrode technology for patients suffering from epilepsy, chronic back pain, and Parkinson's disease. In his letter, Dave Rosa, Chief Executive Officer of NeuroOne, states, "As we continue to develop ...
“About a third of individuals with epilepsy have drug-resistant seizures. Removal or ablation of the affected temporal lobe can be an option, but many people with epilepsy are not eligible or interested in a tissue-destructive procedure. ...
Patient recruitment is underway at epilepsy centers across the United States. About NRTX-1001 NRTX-1001 is a regenerative neural cell therapy derived from human pluripotent stem cells. ...
Prior to working in the pharmaceutical industry, he was in clinical practice as a neurologist at the Barrow Neurological Institute in Arizona for 10 years, where he was director of the epilepsy program. He has authored or co-authored over 50 full-length papers in neurology-related areas. ...
The data are being presented at the Annual Meeting of the American Epilepsy Society (AES), which is being held December 3-7, 2021, in Chicago, IL. “These preclinical data, in a model of drug-resistant epilepsy, demonstrate that a single administration of NRTX-1001 achieves durable and significant suppression of seizures and reduction of hippocampal ...